This study will assess the safety, tolerability, pharmacokinetics, and antiviral activity of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.
Interested in Volunteering?
Scientists want to know if a combination of an investigational long-acting HIV drug and a monoclonal antibody given together are safe and effective at maintaining undetectable viral load in people living with HIV.
You may qualify if you:
- are HIV+
- are at least 18 years old
- are on a stable HIV regimen with an undetectable viral load for at least 2 years
- have a CD4 count above 350
- have no active hepatitis B or C
PARTICIPANTS WILL BE COMPENSATED
Raphael Landovitz, MD, MSc
For more information, contact the study team at:
If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.